| DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation R Abbotts, MJ Topper, C Biondi, D Fontaine, R Goswami, L Stojanovic, ... Proceedings of the National Academy of Sciences 116 (45), 22609-22618, 2019 | 75 | 2019 |
| Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency LJ McLaughlin, L Stojanovic, AA Kogan, JL Rutherford, EY Choi, ... Proceedings of the National Academy of Sciences 117 (30), 17785-17795, 2020 | 33 | 2020 |
| Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia MR Baer, AA Kogan, SM Bentzen, T Mi, RG Lapidus, VH Duong, A Emadi, ... Clinical Cancer Research 28 (7), 1313-1322, 2022 | 26 | 2022 |
| Exploiting epigenetically mediated changes: acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment AA Kogan, RG Lapidus, MR Baer, FV Rassool Advances in Cancer Research 141, 213-253, 2019 | 19 | 2019 |
| Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia AA Kogan, MJ Topper, AJ Dellomo, L Stojanovic, LJ McLaughlin, ... Proceedings of the National Academy of Sciences 119 (27), e2123227119, 2022 | 13 | 2022 |
| DNA demethylating agents generate a brcaness effect in multiple sporadic tumor types: prediction for sensitivity to PARP inhibitors in AML AA Kogan, LJ Mclaughlin, M Topper, N Muvarak, L Stojanovic, TM Creed, ... Blood 130, 3347, 2017 | 6 | 2017 |
| DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML AA Kogan, MJ Topper, L Stojanovic, LJ McLaughlin, TJ Kingsbury, ... Cancer Research 82 (12_Supplement), 6301-6301, 2022 | 1 | 2022 |
| The combination of PARP inhibitors and DNMT inhibitors modulates immune activity and suggests a role for immune therapy in AML AA Kogan, M Topper, SC Shissler, MS Lee, DR Bollino, EY Choi, ... Blood 132 (Supplement 1), 3886-3886, 2018 | 1 | 2018 |
| ITI-1020, a novel PDE type 1 inhibitor, reduces tumor growth in triple negative breast cancer (TNBC) mouse models M Voisin, AA Kogan, S Goding, GL Snyder, RE Davis Cancer Research 83 (7_Supplement), 487-487, 2023 | | 2023 |
| Activating STING-Dependent Immune Signaling in AML AA Kogan University of Maryland, Baltimore, 2021 | | 2021 |
| Pharmacologic induction of innate immune signaling via STING directly drives homologous recombination deficiency LJ McLaughlin, AA Kogan, SB Baylin, MJ Topper, FV Rassool Cancer Research 80 (16_Supplement), 969-969, 2020 | | 2020 |
| DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors AA Kogan, LJ Mclaughlin, MR Baer, S Baylin, M Topper, FV Rassool Blood 134, 3763, 2019 | | 2019 |
| DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia LJ McLaughlin, AA Kogan, EY Choi, RS Lapidus, Y Zou, H Li, SB Baylin, ... Cancer Research 79 (13_Supplement), 4473-4473, 2019 | | 2019 |
